Clene Inc.
NASDAQ:CLNN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Clene Inc.
Short-Term Investments
Clene Inc.
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clene Inc.
NASDAQ:CLNN
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Short-Term Investments
$28m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Short-Term Investments
$68m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-28%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Short-Term Investments
$1.5B
|
CAGR 3-Years
77%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Short-Term Investments
$5.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
32%
|
CAGR 10-Years
37%
|
|
Clene Inc.
Glance View
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 95 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.
